{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:20:20Z","timestamp":1790648420436,"version":"4.1.0"},"reference-count":76,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>\n                    Plazomicin is a novel aminoglycoside antibiotic that binds to the bacterial 30S ribosomal subunit, thus inhibiting protein synthesis in a concentration\u2010dependent manner. Plazomicin displays a broad spectrum of activity against aerobic gram\u2010negative bacteria including extended\u2010spectrum \u03b2\u2010lactamase\u2013producing Enterobacteriaceae, carbapenem\u2010resistant Enterobacteriaceae, and organisms with aminoglycoside\u2010modifying enzymes. In a large phase\n                    <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>\n                    clinical trial, plazomicin was shown to be noninferior to meropenem in the treatment of complicated urinary tract infections (\n                    <jats:styled-content style=\"fixed-case\">cUTI<\/jats:styled-content>\n                    s) with respect to the coprimary efficacy end points of the microbiologically modified intent\u2010to\u2010treat composite cure rate at day 5 (plazomicin 88% [168\/191 subjects] vs meropenem 91.4% [180\/197]) and at the test\u2010of\u2010cure visit (plazomicin 81.7% [156\/191] vs meropenem 70.1% [138\/197]). In a small phase\n                    <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>\n                    clinical trial, plazomicin was shown to be effective in the treatment of infections caused by carbapenem\u2010resistant Enterobacteriaceae. It was associated with a lower all\u2010cause mortality or significant disease\u2010related complication rate (23.5% [4\/17]) compared with colistin (50% [10\/20]). The most common adverse reactions associated with plazomicin are decreased renal function, diarrhea, hypertension, headache, nausea, vomiting, and hypotension. As with other aminoglycosides, plazomicin may cause neuromuscular blockade, ototoxicity, and fetal harm in pregnant women. Due to limited efficacy and safety data, plazomicin is indicated for the treatment of\n                    <jats:styled-content style=\"fixed-case\">cUTIs<\/jats:styled-content>\n                    in adults with limited or no alternative treatment options, using a dosage regimen of 15\u00a0mg\/kg intravenously every 24\u00a0hours for 4\u20137\u00a0days. Dosage reductions and therapeutic drug monitoring are warranted in patients with moderate or severe renal impairment. Plazomicin is not recommended in patients with severe renal impairment including those receiving renal replacement therapy. With the approval of plazomicin, clinicians now have an additional option for the treatment of adults with\n                    <jats:styled-content style=\"fixed-case\">cUTI<\/jats:styled-content>\n                    s, particularly those caused by multidrug\u2010resistant gram\u2010negative rods.\n                  <\/jats:p>","DOI":"10.1002\/phar.2203","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T05:09:23Z","timestamp":1543900163000},"page":"77-93","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Plazomicin: A Next\u2010Generation Aminoglycoside"],"prefix":"10.1002","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1244-8422","authenticated-orcid":false,"given":"Kristy M.","family":"Shaeer","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapeutics and Clinical Research University of South Florida College of Pharmacy Tampa Florida"},{"name":"Department of Internal Medicine University of South Florida Morsani College of Medicine Tampa Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika T.","family":"Zmarlicka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Maricopa Medical Center Phoenix Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias B.","family":"Chahine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Palm Beach Atlantic University Lloyd L. Gregory School of Pharmacy West Palm Beach Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Piccicacco","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Tampa General Hospital Tampa Florida"},{"name":"The University of Texas at Tyler Ben and Maytee Fisch College of Pharmacy Tyler Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Cho","sequence":"additional","affiliation":[{"name":"The University of Texas at Tyler Ben and Maytee Fisch College of Pharmacy Tyler Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2018.58"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1636"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2018.03.013"},{"key":"e_1_2_15_5_1","unstructured":"Centers for Disease Control and Prevention. Antibiotic\/Antimicrobial Resistance: Biggest Threats 2013. Available fromhttps:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf. Accessed June 29 2018."},{"key":"e_1_2_15_6_1","unstructured":"World Health Organization. Global Priority List of Antibiotic\u2010Resistant Bacteria to Guide Research Discovery and Development of New Antibiotics 2018. Available fromhttp:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1. Accessed June 29 2018."},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01041-09"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01709-16"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccc.2010.11.006"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/665724"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq459"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02744-13"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx239"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00873-15"},{"key":"e_1_2_15_15_1","unstructured":"Achaogen Inc.Zemdri (plazomicin) for injection package insert.South San Francisco CA;2018."},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1586\/eri.12.25"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2010.09.004"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00572-10"},{"key":"e_1_2_15_19_1","unstructured":"National Center for Biotechnology Information. Sisomicin Sulfate Compound Summary PubChem Compound Database [internet]. Bethesda MD: NCBI;2018. Available fromhttps:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/6420034. Accessed June 5 2018."},{"key":"e_1_2_15_20_1","unstructured":"MartinsAF BailL ItoC RochaJ SerioAW DalmolinT.Antimicrobial activity of plazomicin against Enterobacteriaceae producing carbapenemases from 50 Brazilian medical centers [Poster 4127]. Presented at the 2017 American Society for Microbiology MicrobeNew Orleans LA June 1\u20135 2017."},{"key":"e_1_2_15_21_1","unstructured":"GalaniISM DaikosG ChrysouliZ et\u00a0al.Activity of ACHN\u2010490 against MDR clinical isolates of Klebsiella pneumoniae Escherichia coli and Enterobacter spp. from Athens Greece [Poster 1147]. Presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases Milan Italy May 7\u201310 2011."},{"key":"e_1_2_15_22_1","unstructured":"GalaniINK AdamouP KaraiskosI GiamarellouH SouliM.Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals in regards to plazomicin and aminoglycoside resistance [Poster 0406]. Presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases Vienna Austria April 22\u201325 2017."},{"key":"e_1_2_15_23_1","unstructured":"CastanheiraMSJ ArendsSJR FlammRK.Activity of Plazomicin and Comparator Agents Tested against Contemporary Clinical Isolates Collected Worldwide [Poster 645]. Presented at the ASM Microbe Atlanta GA June 7\u201311 2018."},{"key":"e_1_2_15_24_1","unstructured":"CastanheiraMMR DoyleTB StreitJM SerioAW KrauseKM FlammRK.Plazomicin activity against Enterobacteriaceae collected from Europe Latin America and Asia\u2010Pacific during 2016 including those with aminoglycoside and beta\u2010lactam resistance mechanisms [Poster P0093]. Presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases Madrid Spain April 21\u201324 2018."},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx261"},{"key":"e_1_2_15_26_1","unstructured":"HeineHSML HalasohorisS HolmanK et\u00a0al.Activity and efficacy of ACHN\u2010490 a broad\u2010spectrum next\u2010generation aminoglycoside against Yersinia pestis and Francisella tularensis [Poster 210]. Presented at the 48th Annual Meeting of the Infectious Diseases Society of America Vancouver BC Canada October 21\u201324 2010."},{"key":"e_1_2_15_27_1","unstructured":"CitronDMTK LeoncioE SerioAW KrauseKM GoldsteinEJC.In vitro activity of plazomicin (PLZ) and comparators against facultative anaerobes incubated aerobically and anaerobically and obligate anaerobes [Poster 333]. Presented at the 2017 American Society for Microbiology Microbe New Orleans LA June 1\u20135 2017."},{"key":"e_1_2_15_28_1","unstructured":"U.S. Food and Drug Administration Antimicrobial Drugs Advisory Committee. FDA briefing document: plazomicin (NDA 210303). Available fromhttps:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM606040.pdf. Accessed June 5 2018."},{"key":"e_1_2_15_29_1","unstructured":"U.S. Food and Drug Administration Antimicrobial Drugs Advisory Committee. FDA briefing document: plazomicin sulfate injection (NDA 210303). Available fromhttps:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM606039.pdf. Accessed August 10 2018."},{"key":"e_1_2_15_30_1","unstructured":"LopezMCPJ SimaluizaJR Rodr\u00edguez\u2010AvialI CulebrasE.Plazomicin has potent in\u00a0vitro activity against methicillin\u2010resistant Staphylococcus aureus (MRSA) isolates carrying different aminoglycoside\u2010modifying enzymes [Poster 0240]. Presented at the 25th European Congress of Clinical Microbiology and Infectious Diseases Copenhagen Denmark April 25\u201328 2015."},{"key":"e_1_2_15_31_1","unstructured":"ZhanelGAH BaxterM DenisuikA et\u00a0al.In vitro activity of plazomicin against gram\u2010negative and gram\u2010positive pathogens isolated from patients in Canadian hospitals in 2011\u20102015: CANWARD surveillance study [Poster 3]. Presented at the 2017 American Society for Microbiology Microbe New Orleans LA June 1\u20135 2017."},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.05.016"},{"key":"e_1_2_15_33_1","doi-asserted-by":"crossref","unstructured":"CastanheiraMDL HublerCM MendesRE SerioAW KrauseKM FlammRK.Activity of plazomicin against Enterobacteriaceae isolates collected in the United States including isolates carrying aminoglycoside\u2010modifying enzymes detected by whole genome sequencing [Poster 1235]. Presented at IDWeek 2017 San Diego CA October 4\u20138 2017.","DOI":"10.1093\/ofid\/ofx163.931"},{"key":"e_1_2_15_34_1","doi-asserted-by":"crossref","unstructured":"CastanheiraMMR StreitJM FlammRK.Activity of plazomicin and comparator agents tested against gram\u2010negative and \u2010positive clinical isolates collected in USA hospitals during 2015 [Poster 1822]. Presented at IDWeek 2016 New Orleans LA October 26\u201330 2016.","DOI":"10.1093\/ofid\/ofw172.1370"},{"key":"e_1_2_15_35_1","unstructured":"ZhangYKA LinX BushK.In vitro activity of plazomicin against 110 carbapenemase\u2010producing Enterobacteriaceae clinical isolates [Poster 554]. Presented at the 2016 American Society for Microbiology Microbe Atlanta GA June 7\u201311 2016."},{"key":"e_1_2_15_36_1","unstructured":"CastanheiraMWA RhombergPR JonesRN.Plazomicin activity against contemporary clinical isolates collected in USA hospitals [Poster C\u2010613]. Presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego CA September 18\u201321 2015."},{"key":"e_1_2_15_37_1","unstructured":"Rodr\u00edguez\u2010AvialIPI Rodr\u00edguez\u2010AvialC PicazoJJ.In vitro activity of plazomicin and comparators against carbapenemase\u2010producing Enterobacteriaceae clinical isolates [Poster P1682]. Presented at the 24th European Congress of Clinical Microbiology and Infectious Diseases Barcelona Spain May 10\u201313 2014."},{"key":"e_1_2_15_38_1","unstructured":"OlafisoyeOAM CortesC UrbanC LandmanD QualeJ.Activity of plazomicin against contemporary isolates of Enterobacteriaceae from New York City [Poster 249]. Presented at IDWeek 2014 Philadelphia PA October 8\u201312 2014."},{"key":"e_1_2_15_39_1","unstructured":"JonesRNAE AggenJB BiedenbachDJ MillerGH.Activity of the neoglycoside ACHN\u2010490 against a contemporary collection of clinical isolates including antimicrobial\u2010resistant strains [Poster F1\u2010846a]. Presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco CA September 12\u201315 2009."},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq408"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1086\/518605"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00748-08"},{"key":"e_1_2_15_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.7.2949-2953.2005"},{"key":"e_1_2_15_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2012.05.001"},{"key":"e_1_2_15_45_1","unstructured":"CastanheiraMDT WoosleyLN SerioAW KrauseKM FlammRK.Plazomicin activity against European Enterobacteriaceae isolates carrying aminoglycoside\u2010modifying enzymes and 16s rRNA methylases [P1281]. Poster presented at the European Congress of Clinical Microbiology and Infectious Diseases Vienna Austria April 22\u201325 2017."},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00624-11"},{"key":"e_1_2_15_47_1","unstructured":"Van WartSABS ForrestA BrussJ CassR AmbrosePG.Population pharmacokinetics of ACHN\u2010490 injection in healthy subjects [Poster 209]. Presented at the 48th Annual Meeting of the Infectious Diseases Society of America Vancouver BC Canada October 21\u201324 2010."},{"key":"e_1_2_15_48_1","unstructured":"CassRKC GotfriedM RodvoldK TackKJ BrussJ.A double\u2010blind randomized placebo\u2010controlled study to assess the safety tolerability plasma pharmacokinetics and lung penetration of intravenous plazomicin in healthy subjects [Poster 1637]. Presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases Berlin Germany April 27\u201330 2013."},{"key":"e_1_2_15_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.16.6.767"},{"key":"e_1_2_15_50_1","unstructured":"SeroogyJCT GallJ Van WartS.Pharmacokinetics (PK) of plazomicin in health adults [Poster 206]. Presented at the American Society for Microbiology and the European Society for Clinical Microbiology and Infectious Diseases Conference Boston MA September 6\u20138 2017."},{"key":"e_1_2_15_51_1","unstructured":"RiddleVCD KostrubC MaL Van WartSA HillanKJ.The pharmacokinetics and safety of plazomicin In subjects with renal impairment [Poster 918]. Presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases Berlin Germany April 27\u201330 2013."},{"key":"e_1_2_15_52_1","doi-asserted-by":"publisher","DOI":"10.1086\/514620"},{"key":"e_1_2_15_53_1","unstructured":"ZurenkoGSD KnechtelM NicholsN et\u00a0al.The bactericidal activity of the neoglycoside ACHN\u2010490 against aminoglycoside\u2010resistant bacteria [Poster F1\u2010841]. Presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco CA September 12\u201315 2009."},{"key":"e_1_2_15_54_1","unstructured":"LouieAKC FikesS LiuW FeeneyLA ConnollyL DrusanoG.Plazomicin demonstrates potent efficacy against carbapenem\u2010resistant Enterobacteriaceae (CRE) in the neutropenic mouse thigh infection model [Poster 2961]. Presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases Berlin Germany April 27\u201330 2013."},{"key":"e_1_2_15_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01390-10"},{"key":"e_1_2_15_56_1","unstructured":"SerioAWKA ArmstrongES MillerG KrauseKM.Plazomicin a Novel Aminoglycoside Exhibits a Post\u2010Antibiotic Effect Against Enterobacteriaceae [Poster A\u2010052]. Presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego CA September 18\u201321 2015."},{"key":"e_1_2_15_57_1","unstructured":"HallDTM ShinabargerD SerioA KrauseKM PillarC.Investigating the Post\u2010Antibiotic Effect of Plazomicin against Multidrug\u2010Resistant Enterobacteriaceae [Poster 205]. Presented at the 2017 American Society for Microbiology Microbe New Orleans LA June 1\u20135 2017."},{"key":"e_1_2_15_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01350-09"},{"key":"e_1_2_15_59_1","unstructured":"Van WartSAFA DrusanoGL BhavnaniSM et\u00a0al.Pharmacokinetic\u2010Pharmacodynamic Analysis Predicts a High Probability of Efficacy for Plazomicin Against Serious Infections Caused by Carbapenem\u2010Resistant Enterobacteriaceae [Poster P\u2010914]. Presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases Berlin Germany April 27\u201330 2013."},{"key":"e_1_2_15_60_1","unstructured":"Van WartS ForrestA BulikCC et\u00a0al.Pharmacokinetic\u2010Pharmacodynamic Assessment Predicts High Efficacy for Plazomicin Against Serious Infections Caused by Carbapenem\u2010Resistant Klebsiella pneumoniae [Poster A\u20101054c]. Presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy Denver CO September 10\u201313 2013."},{"key":"e_1_2_15_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01989-17"},{"key":"e_1_2_15_62_1","doi-asserted-by":"crossref","unstructured":"CloutierDJML KomirenkoAS CebrikDS et\u00a0al.Evaluating once\u2010daily plazomicin versus meropenem for the treatment of complicated urinary tract infection and acute pyelonephritis: results from a phase 3 study (EPIC). Poster presented at the American Society for Microbiology Microbe New Orleans LA June 1\u20135 2017.","DOI":"10.1093\/ofid\/ofx163.1385"},{"key":"e_1_2_15_63_1","unstructured":"ConnollyLEJA O'KeeffeB SerioAW et\u00a0al.Plazomicin is associated with improved survival and safety compared with colistin in the treatment of serious infections due to carbapenem\u2010resistant Enterobacteriaceae: results of the CARE study [OS0250F]. Presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases Vienna Austria April 22\u201325 2017."},{"key":"e_1_2_15_64_1","doi-asserted-by":"crossref","unstructured":"McKinnellJCL PushkinR JubbA et\u00a0al.Improved Outcomes with Plazomicin (PLZ) Compared with Colistin (CST) in Patients with Bloodstream Infections (BSI) Caused by Carbapenem\u2010resistant Enterobacteriaceae (CRE): Results from the CARE Study (#1853). Poster presented at IDWeek San Diego CA October 4\u20138 2017.","DOI":"10.1093\/ofid\/ofx163.1383"},{"key":"e_1_2_15_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2016.08.047"},{"key":"e_1_2_15_66_1","unstructured":"RiddleVMJ CebrikD KostrubC FongL HillanKJ.The Effect of Plazomicin Injection on the QT\/QTc Interval in Healthy Volunteers [A\u2010017f]. Presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy Denver CO September 10\u201313 2013."},{"key":"e_1_2_15_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1649"},{"key":"e_1_2_15_68_1","unstructured":"UrbancicK GraysonML.Chapter 51: Kanamycin. In: Kucers\u2019The Use of Antibiotics: A Clinical Review of Antibacterial Antifungal Antiparasitic and Antiviral Drugs 7th edn.Boca Raton FL:CRC Press;2017:950\u2013964."},{"key":"e_1_2_15_69_1","unstructured":"Bristol\u2010Myers Squibb Company.Glucophage (metformin) for tablet package insert.Princeton NJ;2018."},{"key":"e_1_2_15_70_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp170839"},{"key":"e_1_2_15_71_1","unstructured":"GlobeNewswire.Achaogen Zemdri (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI). Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI). Available fromhttps:\/\/globenewswire.com\/news-release\/2018\/06\/26\/1529573\/0\/en\/ZEMDRITM-plazomicin-Approved-by-FDA-for-the-Treatment-of-Adults-with-Complicated-Urinary-Tract-Infections-cUTI.html. Accessed June 26 2018."},{"key":"e_1_2_15_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01074-18"},{"issue":"3","key":"e_1_2_15_73_1","first-page":"287","article-title":"Clostridium difficile infection","volume":"373","author":"Leffler DA","year":"2015","journal-title":"N Engl J Med"},{"key":"e_1_2_15_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2013.11.006"},{"key":"e_1_2_15_75_1","unstructured":"Achaogen Inc.Plazomicin Susceptibility Testing Materials 2018. Available fromhttp:\/\/www.zemdri.com\/assets\/pdf\/AST-Information-Sheet.pdf. Accessed August 31 2018."},{"key":"e_1_2_15_76_1","unstructured":"Achaogen Inc.Plazomicin Therapeutic Drug Monitoring Testing at Mayo Clinic 2018. Available fromhttp:\/\/www.zemdri.com\/assets\/pdf\/TDM-Information-Sheet.pdf. Accessed August 31 2018."},{"key":"e_1_2_15_77_1","unstructured":"Achaogen Inc.CMS Grants New Technology Add\u2010on Payment to ZEMDRI (plazomicin) 2018. Available fromhttp:\/\/investors.achaogen.com\/news-releases\/news-release-details\/cms-grants-new-technology-add-payment-zemdritm-plazomicin. Accessed October 26 2018."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2203","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2203","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2203","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:33:15Z","timestamp":1761042795000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1002\/phar.2203"],"URL":"https:\/\/doi.org\/10.1002\/phar.2203","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"2019-01-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}